Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
NCT ID | NCT03816163 |
Title | A Study to Assess the Efficacy and Safety of IMAB362 in Combination With Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment in Subjects With Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma |
Recruitment | Active, not recruiting |
Gender | both |
Phase | Phase II |
Variant Requirements | No |
Sponsors | Astellas Pharma Global Development, Inc. |
Indications | |
Therapies | |
Age Groups: | adult | senior |
Covered Countries | USA | ITA | FRA | ESP | AUS |